Novartis taps Lindy to turn biologic drugs into at-home injectables, puts nearly $1B on the line

Novartis has formed a strategic collaboration with drug delivery specialist Lindy Biosciences to develop self-administered versions of the Swiss pharma’s innovative drugs.